Wednesday, July 8, 2026

Patent intelligence · US

US 10046010

Methods of generating mesenchymal stem cells which secrete neurotrophic factors

granted A61KA61K2035/124A61K35/28A61P
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 12
Applicant portfolio 8
Patent details — US 10046010
Jurisdiction
US
Status
granted
Grant date
Aug 14, 2018
Expiration
Aug 9, 2038
Claims
12
CPC classes
A61K, A61K2035/124, A61K35/28, A61P
View on Google Patents ↗

Quick answer

US 10046010 (Methods of generating mesenchymal stem cells which secrete neurotrophic factors) is held by BRAINSTORM CELL THERAPEUTICS LTD.. Status: granted. Granted Aug 14, 2018. Expires Aug 9, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
12
CPC classes
A61K, A61K2035/124, A61K35/28, A61P, A61P21/00, A61P21/04

More from BRAINSTORM CELL THERAPEUTICS LTD.

Related pharmaceutical patents in our USPTO index.

  1. US 12233092

    MSC-NTF specific exosomes and use thereof

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Feb 20, 2045

    granted
  2. US 11185572

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Nov 25, 2041

    granted
  3. US 10564149

    Populations of mesenchymal stem cells that secrete neurotrophic factors

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Feb 13, 2040

    granted
  4. US 10052363

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Aug 16, 2038

    granted
  5. US 9474787

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Oct 20, 2036

    granted
  6. US 8900574

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Nov 27, 2034

    granted
  7. US 8663987

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Expires Feb 27, 2034

    granted

Frequently asked questions

What is US patent 10046010?

US 10046010 (Methods of generating mesenchymal stem cells which secrete neurotrophic factors) is held by BRAINSTORM CELL THERAPEUTICS LTD.. Status: granted. Granted Aug 14, 2018. Expires Aug 9, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10046010?

BRAINSTORM CELL THERAPEUTICS LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.

When does US 10046010 expire?

Our index shows an expiration date of Aug 9, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.